SCHEMBL1967409

SCHEMBL1967409

CCOC(=O)c1cc([N+](=O)[O-])c(NCc2ccccc2)cc1OCC(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 3/20 0.44
POLB P06746 3/20 0.44
GALR2 O43603 1/20 0.44
MITF O75030 1/20 0.44
HSP90AA1 P07900 1/20 0.44
XBP1 P17861 1/20 0.44
CCR6 P51684 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
PKM P14618 2/20 0.44
MAPT P10636 10/20 0.43
KMT2A Q03164 4/20 0.43
CRHBP P24387 3/20 0.43
CRHR2 Q13324 3/20 0.43
MEN1 O00255 3/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974278 0.91 L3MBTL1 (0.50) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1967194 0.84 ALDH1A1 (0.49) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1969432 0.82 ALDH1A1 (0.64) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1966811 0.79 ALDH1A1 (0.47) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL2698732 0.78 MAPT (0.58) RAB9AALDH1A1SMN1; SMN2LMNAPOLB
SCHEMBL1608610 0.76 ALOX15 (0.58) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1970277 0.75 MAPT (0.51) ALDH1A1SMN1; SMN2LMNAHPGDPOLB
SCHEMBL6582296 0.74 SMN1; SMN2 (0.65) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL23044867 0.74 ALDH1A1 (0.48) RAB9ANPSR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1971829 0.73 GAA (0.49) ALDH1A1SMN1; SMN2LMNAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed
WO-2010034796-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 RAB9A 867/4885NPSR1 2508/4885ALDH1A1 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.